Nordic Bioscience has announced the global launch of its PRO-C3 test on Roche Diagnostics' cobas analyzers, marking a significant milestone in liver fibrosis diagnostics. The Elecsys® PRO-C3 test, when used in combination with the ADAPT algorithm (age, diabetes status, PRO-C3 levels, and platelets), enables clinicians to assess the severity of liver fibrosis—a key factor in diseases contributing to approximately one in every 25 deaths worldwide. This launch enhances global accessibility by integrating the test into Roche’s widely used cobas e 801 platform, making high-throughput liver fibrosis testing possible in hospital laboratories and routine diagnostic settings.

PRO-C3, developed by Nordic Bioscience, is a proprietary biomarker that quantifies fibrogenesis, especially in chronic liver conditions such as NASH (non-alcoholic steatohepatitis). Previously available only through Nordic Bioscience’s CAP-CLIA certified lab in Denmark, the test’s CE-marked version on Roche’s platform marks its first commercial release from the collaboration between the two companies. This step reflects both companies’ commitment to precision medicine and provides laboratories with tools capable of addressing fibrosis-related pathologies, which are implicated in 40% of deaths in the Western world due to organ damage like liver scarring.

With over a decade of research and more than 250 scientific publications on PRO-C3, Nordic Bioscience has established itself as a leader in fibrosis biomarker development. CEO Morten Karsdal emphasized the importance of making such tools globally accessible, stating, “We are proud that our technology becomes globally available to make a difference for patients.” This launch is not only a commercial achievement but a pivotal advancement in modern clinical chemistry, with PRO-C3 now leading the way for future biomarker releases from Nordic Bioscience’s fibrosis panel.

MedTech Spectrum's Summary

Global Launch on Roche Platform: Nordic Bioscience’s PRO-C3 liver fibrosis test has been launched globally by Roche Diagnostics on the cobas e 801 analyser, expanding its clinical availability.

Proven Clinical Value: The CE-approved Elecsys® PRO-C3 test, used with the ADAPT formula, helps assess liver fibrosis severity—a major global health concern linked to 1 in 25 deaths.

Scientific Leadership: Backed by over 250 scientific publications, PRO-C3 is Nordic Bioscience’s first commercialized biomarker from its fibrosis panel, reinforcing its role in precision medicine.